Use of hematopoietic cell transplantation in younger patients with acute myeloid leukemia

A National Cancer Database Study

Vijaya R Bhatt, Baojiang Chen, Stephanie J. Lee

Research output: Contribution to journalArticle

Abstract

Younger patients with intermediate or high-risk acute myeloid leukemia (AML) obtain overall survival benefit from the upfront use of hematopoietic cell transplantation (HCT). We queried the National Cancer Database to study 19,897 younger patients (18-60 years) with intermediate or high-risk AML reported between 2003-2012. Multivariable logistic regression analysis was performed to identify variables associated with the utilization of HCT. Approximately 18.5% of younger patients received HCT as a part of initial therapy. A lower rate of utilization of HCT was associated with receipt of care in a non-academic hospital, African American race, male sex, age group 50-60 years, Charlson comorbidity score of ≥1, uninsured status, Medicaid or Medicare insurance, and lower educational or income status. The use of HCT in younger patients varies based on non-biologic factors such as race, hospital type, insurance, educational, and income status. Socioeconomic and health system factors contribute to disparity in the uptake of HCT in the US.

Original languageEnglish (US)
Pages (from-to)873-879
Number of pages7
JournalBone marrow transplantation
Volume53
Issue number7
DOIs
StatePublished - Jul 1 2018

Fingerprint

Cell Transplantation
Acute Myeloid Leukemia
Databases
Neoplasms
Insurance
Educational Status
Medicaid
Medicare
African Americans
Comorbidity
Age Groups
Logistic Models
Regression Analysis
Survival
Health

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Use of hematopoietic cell transplantation in younger patients with acute myeloid leukemia : A National Cancer Database Study. / Bhatt, Vijaya R; Chen, Baojiang; Lee, Stephanie J.

In: Bone marrow transplantation, Vol. 53, No. 7, 01.07.2018, p. 873-879.

Research output: Contribution to journalArticle

@article{b23b5469f9434b4b80af64c228108c04,
title = "Use of hematopoietic cell transplantation in younger patients with acute myeloid leukemia: A National Cancer Database Study",
abstract = "Younger patients with intermediate or high-risk acute myeloid leukemia (AML) obtain overall survival benefit from the upfront use of hematopoietic cell transplantation (HCT). We queried the National Cancer Database to study 19,897 younger patients (18-60 years) with intermediate or high-risk AML reported between 2003-2012. Multivariable logistic regression analysis was performed to identify variables associated with the utilization of HCT. Approximately 18.5{\%} of younger patients received HCT as a part of initial therapy. A lower rate of utilization of HCT was associated with receipt of care in a non-academic hospital, African American race, male sex, age group 50-60 years, Charlson comorbidity score of ≥1, uninsured status, Medicaid or Medicare insurance, and lower educational or income status. The use of HCT in younger patients varies based on non-biologic factors such as race, hospital type, insurance, educational, and income status. Socioeconomic and health system factors contribute to disparity in the uptake of HCT in the US.",
author = "Bhatt, {Vijaya R} and Baojiang Chen and Lee, {Stephanie J.}",
year = "2018",
month = "7",
day = "1",
doi = "10.1038/s41409-018-0105-9",
language = "English (US)",
volume = "53",
pages = "873--879",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "7",

}

TY - JOUR

T1 - Use of hematopoietic cell transplantation in younger patients with acute myeloid leukemia

T2 - A National Cancer Database Study

AU - Bhatt, Vijaya R

AU - Chen, Baojiang

AU - Lee, Stephanie J.

PY - 2018/7/1

Y1 - 2018/7/1

N2 - Younger patients with intermediate or high-risk acute myeloid leukemia (AML) obtain overall survival benefit from the upfront use of hematopoietic cell transplantation (HCT). We queried the National Cancer Database to study 19,897 younger patients (18-60 years) with intermediate or high-risk AML reported between 2003-2012. Multivariable logistic regression analysis was performed to identify variables associated with the utilization of HCT. Approximately 18.5% of younger patients received HCT as a part of initial therapy. A lower rate of utilization of HCT was associated with receipt of care in a non-academic hospital, African American race, male sex, age group 50-60 years, Charlson comorbidity score of ≥1, uninsured status, Medicaid or Medicare insurance, and lower educational or income status. The use of HCT in younger patients varies based on non-biologic factors such as race, hospital type, insurance, educational, and income status. Socioeconomic and health system factors contribute to disparity in the uptake of HCT in the US.

AB - Younger patients with intermediate or high-risk acute myeloid leukemia (AML) obtain overall survival benefit from the upfront use of hematopoietic cell transplantation (HCT). We queried the National Cancer Database to study 19,897 younger patients (18-60 years) with intermediate or high-risk AML reported between 2003-2012. Multivariable logistic regression analysis was performed to identify variables associated with the utilization of HCT. Approximately 18.5% of younger patients received HCT as a part of initial therapy. A lower rate of utilization of HCT was associated with receipt of care in a non-academic hospital, African American race, male sex, age group 50-60 years, Charlson comorbidity score of ≥1, uninsured status, Medicaid or Medicare insurance, and lower educational or income status. The use of HCT in younger patients varies based on non-biologic factors such as race, hospital type, insurance, educational, and income status. Socioeconomic and health system factors contribute to disparity in the uptake of HCT in the US.

UR - http://www.scopus.com/inward/record.url?scp=85041577649&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85041577649&partnerID=8YFLogxK

U2 - 10.1038/s41409-018-0105-9

DO - 10.1038/s41409-018-0105-9

M3 - Article

VL - 53

SP - 873

EP - 879

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 7

ER -